Pacira(US:PCRX)2026-02-26 22:30Financial Data and Key Metrics Changes - In 2025, the company achieved $726 million in revenue, marking a significant increase compared to previous years, with the highest gross margins in its history at 80% for Q4 2025, up from 79% in Q4 2024 [5][20] - The fourth quarter sales for EXPAREL increased to $155.8 million from $147.7 million in 2024, reflecting a volume growth of approximately 7% [19] - Non-GAAP R&D expenses rose to $34.4 million in Q4 2025 from $22.0 million in the previous year, while SG&A expenses increased to $91.9 million from $70.6 million [21] Business Line Data and Key Metrics Changes - EXPAREL showed solid performance with volume-based growth driven by expanding education and awareness, increasing commercial payer adoption, and growing demand across care sites [6][19] - ZILRETTA sales remained flat at $33 million in Q4 2025 compared to 2024, while iovera sales grew to $7 million from $6.5 million [19] Market Data and Key Metrics Changes - The company ended 2025 with 102 million lives covered outside of the surgical bundle, indicating a significant shift in payer policies and access to EXPAREL [7][16] - The strategic focus on key markets with high procedural volumes resulted in over 7% volume growth in these markets compared to 2024 [16] Company Strategy and Development Direction - The company is advancing its 5x30 strategy, aiming to help 3 million patients annually by 2030, with a clear focus on innovative, non-opioid pain management therapies [5][12] - Partnerships with J&J MedTech and LG Chem are expected to enhance market access and revenue growth, with LG Chem set to commercialize EXPAREL in select Asia Pacific countries [9][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting the successful execution of the NOPAIN Act and its positive impact on non-opioid stewardship [13][15] - The company anticipates steady top-line growth in 2026, with total revenue guidance set between $745 million and $770 million, and EXPAREL sales expected to be between $600 million and $620 million [23][24] Other Important Information - The company has strengthened its intellectual property estate to 21 patents, providing a solid foundation for EXPAREL's sustained growth [8] - The company executed $150 million in stock repurchases, reducing outstanding shares to approximately 41 million [22] Q&A Session Summary Question: What constitutes a clinically meaningful signal for the OA readout? - Management clarified that the primary focus of the PCRX-201 trial is safety, but they will also look for efficacy trends measured by key secondary endpoints [28][30] Question: What factors could lead to higher or lower EXPAREL sales guidance? - Management indicated that the guidance reflects a cautious approach due to potential headwinds in the elective procedure market, while also highlighting the positive indicators from their investments [37][39] Question: What are the barriers to adoption for EXPAREL? - Management noted that while reimbursement is improving, the focus is now on clinical adoption and ensuring that economic stakeholders recognize the value of EXPAREL [51][56] Question: What headwinds affected ZILRETTA's performance in 2025? - Management explained that prioritizing EXPAREL led to some disruption in ZILRETTA sales, but they expect growth in 2026 with a fully trained J&J sales team [59][61] Question: Will unexpected business development costs continue? - Management acknowledged that while there may be occasional unexpected costs, they are focused on disciplined investments that maximize shareholder value [65][68]